4,763 Shares in Bristol-Myers Squibb (NYSE:BMY) Purchased by Kavar Capital Partners Group LLC

Kavar Capital Partners Group LLC bought a new position in shares of Bristol-Myers Squibb (NYSE:BMY) in the 3rd quarter, Holdings Channel reports. The fund bought 4,763 shares of the biopharmaceutical company’s stock, valued at approximately $246,000.

Other hedge funds and other institutional investors have also modified their holdings of the company. ESL Trust Services LLC bought a new stake in shares of Bristol-Myers Squibb during the 1st quarter worth about $27,000. ORG Wealth Partners LLC acquired a new position in shares of Bristol-Myers Squibb in the 3rd quarter valued at approximately $34,000. LGT Financial Advisors LLC raised its position in shares of Bristol-Myers Squibb by 42.7% in the 2nd quarter. LGT Financial Advisors LLC now owns 759 shares of the biopharmaceutical company’s stock valued at $32,000 after buying an additional 227 shares in the last quarter. Redmont Wealth Advisors LLC acquired a new position in shares of Bristol-Myers Squibb in the 1st quarter valued at approximately $47,000. Finally, MFA Wealth Advisors LLC acquired a new position in shares of Bristol-Myers Squibb in the 2nd quarter valued at approximately $39,000. Institutional investors own 76.41% of the company’s stock.

Bristol-Myers Squibb Trading Down 1.9 %

NYSE:BMY opened at $51.92 on Friday. The firm’s fifty day moving average is $50.75 and its 200-day moving average is $46.41. The company has a debt-to-equity ratio of 2.86, a quick ratio of 1.02 and a current ratio of 1.16. Bristol-Myers Squibb has a 52 week low of $39.35 and a 52 week high of $55.29. The firm has a market cap of $105.25 billion, a P/E ratio of -16.75, a P/E/G ratio of 13.75 and a beta of 0.46.

Bristol-Myers Squibb (NYSE:BMY) last posted its quarterly earnings data on Friday, July 26th. The biopharmaceutical company reported $2.07 EPS for the quarter, beating analysts’ consensus estimates of $1.64 by $0.43. Bristol-Myers Squibb had a negative net margin of 14.06% and a positive return on equity of 12.51%. The company had revenue of $12.20 billion for the quarter, compared to analyst estimates of $11.54 billion. During the same period in the prior year, the firm posted $1.75 EPS. The company’s quarterly revenue was up 8.7% on a year-over-year basis. Equities analysts expect that Bristol-Myers Squibb will post 0.77 earnings per share for the current year.

Bristol-Myers Squibb Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, November 1st. Stockholders of record on Friday, October 4th will be paid a $0.60 dividend. This represents a $2.40 dividend on an annualized basis and a dividend yield of 4.62%. The ex-dividend date is Friday, October 4th. Bristol-Myers Squibb’s dividend payout ratio is currently -77.42%.

Analyst Upgrades and Downgrades

BMY has been the subject of several analyst reports. TD Cowen boosted their target price on shares of Bristol-Myers Squibb from $53.00 to $59.00 and gave the company a “hold” rating in a research report on Monday, October 7th. Sanford C. Bernstein initiated coverage on shares of Bristol-Myers Squibb in a research report on Thursday, October 17th. They set a “market perform” rating and a $56.00 price objective for the company. Deutsche Bank Aktiengesellschaft lowered their price objective on shares of Bristol-Myers Squibb from $53.00 to $45.00 and set a “hold” rating for the company in a research report on Tuesday, July 23rd. Citigroup cut shares of Bristol-Myers Squibb from a “buy” rating to a “neutral” rating and lowered their price objective for the stock from $75.00 to $55.00 in a research report on Friday. Finally, Cantor Fitzgerald reiterated a “neutral” rating and set a $50.00 price objective on shares of Bristol-Myers Squibb in a research report on Friday, October 18th. Two equities research analysts have rated the stock with a sell rating, fifteen have issued a hold rating, one has given a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, Bristol-Myers Squibb has a consensus rating of “Hold” and a consensus target price of $53.31.

Bristol-Myers Squibb Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.